The Use of Steovess/Binosto After Denosumab Discontinuation to Prevent Increase in Bone Turnover
Status:
Recruiting
Trial end date:
2022-09-30
Target enrollment:
Participant gender:
Summary
It is hypothesized that effervescent alendronate will be able to maintain bone turnover
markers within the pre-menopausal reference range and thereby reducing the likelihood of bone
turnover associated changes (rebound effect), after discontinuation of denosumab treatment in
a non-osteoporotic population.